Inizio has appointed Ryan Quigley as its new chief executive officer, effective yesterday (September 9, 2025).

Quigley, who joined Inizio as chief operating officer in 2021, succeeds Paul Taaffe. Taaffe will remain with the company to support the transition until the end of the year and will continue as a board member.

Quigley’s career spans more than 25 years in healthcare and pharmaceuticals, including senior leadership roles at Abbott and AbbVie. At Inizio, he has overseen commercial strategy, investment plans and innovation.

Ryan Quigley said: “This is an exciting time to lead Inizio as we continue to grow and help biopharma clients with integrated solutions to bring highly complex new drugs to market. At Inizio, it’s the combination of our people and our expertise that makes the difference: we connect talent from across the organization to create innovative solutions that make a meaningful difference for our clients and patients.”

Liam FitzGerald, chairman of the board, added: “Ryan has an exceptional track record as a leader who combines strategic vision with deep operational expertise. He embodies the values of Inizio and has the energy, ambition and client focus to lead the business into its next chapter of growth and success.”

Paul Taaffe has led Inizio since its creation, overseeing its growth into a global business with five divisions – medical, advisory, Evoke, Engage and biotech – and will continue to support the company as a director.